BioMérieux Wins FDA Clearance

July 1, 2016

BioMérieux has won FDA clearance for the expanded use of its Vidas BRAHMS PCT assay, which is intended for managing sepsis in patients with an increased risk of mortality.

The clearance will allow the company to use the change in PCT levels over time to facilitate management of sepsis patients after the initial diagnosis. — Anisa Jibrell

View today's stories